VERAXA Biotech (NASDAQ: VRXA) has announced the successful closing of its previously announced business combination with Voyager Acquisition Corp., resulting in the formation of VERAXA Biotech AG, which began trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. The company is developing a pipeline of bispecific T-cell engagers and antibody-drug conjugates based on its proprietary BiTAC platform, designed to selectively target cancer cells while sparing healthy tissue.
Proceeds from recently completed financings, including a $27.5 million senior secured note and a securities purchase agreement of up to $50 million, are expected to support advancement of its BiTAC-TCE and BiTAC-ADC programs toward clinical development. The company recently presented preclinical data at the AACR Annual Meeting 2026 demonstrating favorable efficacy and safety characteristics for its lead BiTAC-TCE candidate.
This listing on Nasdaq provides VERAXA with access to public capital markets, which could accelerate the development of its novel cancer therapies. For leaders in the biotech and pharmaceutical industries, the progress of VERAXA’s BiTAC platform represents a potential shift in how cancer treatments are designed, with an emphasis on targeting cancer cells while minimizing damage to healthy tissue. The successful business combination also highlights the continued role of special purpose acquisition companies (SPACs) in bringing innovative biotech firms to public markets, despite a broader slowdown in SPAC activity.
The company’s pipeline includes bispecific T-cell engagers that harness the immune system to attack tumors, and antibody-drug conjugates that deliver toxic payloads directly to cancer cells. If clinical trials confirm the preclinical data, these therapies could offer new options for patients with hard-to-treat cancers, potentially reshaping treatment paradigms. For investors, the debut of VRXA on Nasdaq adds a new pure-play oncology biotech to watch, though the forward-looking statements in the company’s filings caution that actual results may differ materially from expectations.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research. The company’s BiTAC platform is guided by rigorous quality-by-design principles, aiming to rapidly advance its pipeline into clinical development and beyond. Voyager Acquisition Corp., the SPAC that merged with VERAXA, was formed with a mission to revolutionize the healthcare sector through business combinations, leveraging a team with expertise in investing, operations, and medical innovation.
For more information, visit VERAXA Biotech at www.veraxa.com and Voyager Acquisition Corp. at https://www.voyageracq.com. The full press release is available at https://ibn.fm/ka00j. Forward-looking statements in this article are subject to risks and uncertainties detailed in the company’s filings with the SEC, including under "Risk Factors" in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
